Jagsonpal Introduces India’s First Hormone Replacement Therapy

On May 24, 2024, Jagsonpal Pharmaceuticals Limited informed the exchanges about the launch of MemUp, India’s first hormone replacement therapy (HRT) that features a US FDA-approved combination of bioidentical estradiol and bio-identical progesterone in a single daily oral capsule.

MemUp represents a major advancement in women’s healthcare, providing an innovative solution for managing vasomotor symptoms of menopause, including night sweats, sleep disturbances and hot flashes.

The company stated that more than 130 million Indian women are currently in menopause or approaching it. The average age at which Indian women experience menopause is 46.2 years. Despite its prevalence, the understanding and awareness related to menopause and its management are less.

MemUp is developed to precisely address this gap and support the critical demand for innovative and effective treatments. The unique combination mimics the body’s natural hormones, offering a more balanced and natural approach to HRT. This innovative formulation simplifies the treatment regimen and improves patient compliance and results.

MemUp will be available at retailers across India and can be purchased by submitting a valid prescription issued by a registered medical practitioner.

The launch also marks an important step in Jagsonpal’s commitment to women’s health, coinciding with the unveiling of the website www.mysakhi.in. This website is a vital part of Jagsonpal’s Corporate Social Responsibility (CSR) initiative, which focuses on enhancing the health and well-being of women at all stages of life, from adolescence through menopause.

The company is also launching extensive outreach programs targeting women and families to raise awareness about menopause, encourage early diagnosis, and improve management practices through various educational campaigns and support networks. Acknowledging India’s diverse linguistic landscape, the content will be available in nine regional languages in addition to Hindi and English. This ensures that women across the country can access the information and support they need in their preferred language.

Speaking of this development, the Managing Director, Mr Manish Gupta, said, “The launch of MemUp strengthens Jagsonpal’s commitment to the gynaecological segment with one of the widest range of offerings of products catering to various conditions and its successful management. In the coming quarters, the company will continue to bolster its presence with novel and customised formulations within the Gynaecological category.”

On May 24, 2024, the share price of Jagsonpal Pharmaceuticals Ltd opened at ₹333.40, touching the day’s high at ₹349.55, as of 10:19 AM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.